Logo image of XL

XL FLEET CORP (XL) Stock Fundamental Analysis

USA - NYSE:XL - US9837FR1002 - Common Stock

1.14 USD
+0.27 (+30.91%)
Last: 11/11/2022, 8:04:00 PM
1.07 USD
-0.07 (-6.14%)
After Hours: 11/11/2022, 8:04:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XL. XL was compared to 83 industry peers in the Automobile Components industry. Both the profitability and financial health of XL have multiple concerns. XL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XL has reported negative net income.
XL had a negative operating cash flow in the past year.
XL Yearly Net Income VS EBIT VS OCF VS FCFXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 0 20M -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -14.54%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XL Yearly ROA, ROE, ROICXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 100 -100 -200 -300

1.3 Margins

Industry RankSector Rank
OM -346.62%
PM (TTM) -270.63%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XL Yearly Profit, Operating, Gross MarginsXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 100 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

XL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XL has been increased compared to 1 year ago.
The debt/assets ratio for XL is higher compared to a year ago.
XL Yearly Shares OutstandingXL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 50M 100M
XL Yearly Total Debt VS Total AssetsXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 100M 200M 300M

2.2 Solvency

XL has an Altman-Z score of 5.34. This indicates that XL is financially healthy and has little risk of bankruptcy at the moment.
XL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.34
ROIC/WACCN/A
WACC10.23%
XL Yearly LT Debt VS Equity VS FCFXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

XL has a Current Ratio of 29.07. This indicates that XL is financially healthy and has no problem in meeting its short term obligations.
XL has a Quick Ratio of 27.87. This indicates that XL is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 29.07
Quick Ratio 27.87
XL Yearly Current Assets VS Current LiabilitesXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

XL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.15%, which is quite impressive.
XL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.10%.
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-23.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.52%

3.2 Future

Based on estimates for the next years, XL will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.59% on average per year.
The Revenue is expected to grow by 81.97% on average over the next years. This is a very strong growth
EPS Next Y-171.92%
EPS Next 2Y-84.92%
EPS Next 3Y-71.3%
EPS Next 5Y-14.59%
Revenue Next Year80.69%
Revenue Next 2Y77.77%
Revenue Next 3Y98.9%
Revenue Next 5Y81.97%

3.3 Evolution

XL Yearly Revenue VS EstimatesXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M 250M
XL Yearly EPS VS EstimatesXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XL Price Earnings VS Forward Price EarningsXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.48
XL Per share dataXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

XL's earnings are expected to decrease with -71.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.92%
EPS Next 3Y-71.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XL FLEET CORP

NYSE:XL (11/11/2022, 8:04:00 PM)

After market: 1.07 -0.07 (-6.14%)

1.14

+0.27 (+30.91%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)11-09 2022-11-09/amc
Earnings (Next)02-27 2023-02-27
Inst Owners0%
Inst Owner Change0%
Ins Owners7.17%
Ins Owner Change0%
Market Cap164.30M
Analysts40
Price Target6.12 (436.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.31%
Min EPS beat(2)54.31%
Max EPS beat(2)54.31%
EPS beat(4)4
Avg EPS beat(4)53.99%
Min EPS beat(4)51.46%
Max EPS beat(4)55.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.08%
Min Revenue beat(2)-48.73%
Max Revenue beat(2)-17.42%
Revenue beat(4)1
Avg Revenue beat(4)-13.34%
Min Revenue beat(4)-48.73%
Max Revenue beat(4)49.94%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.65
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA 2.48
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.13
BVpS2.33
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -346.62%
PM (TTM) -270.63%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.07
Quick Ratio 27.87
Altman-Z 5.34
F-Score2
WACC10.23%
ROIC/WACCN/A
Cap/Depr(3y)80.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-171.92%
EPS Next 2Y-84.92%
EPS Next 3Y-71.3%
EPS Next 5Y-14.59%
Revenue 1Y (TTM)-23.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.52%
Revenue Next Year80.69%
Revenue Next 2Y77.77%
Revenue Next 3Y98.9%
Revenue Next 5Y81.97%
EBIT growth 1Y-74.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.6%
EBIT Next 3Y-0.41%
EBIT Next 5Y-5.92%
FCF growth 1Y-404.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-387.62%
OCF growth 3YN/A
OCF growth 5YN/A